Pharma Marketing Network

The distinction between pharma brand managers and corporate communications is a distinction without much of a difference these days, especially with regard to social media. There are many

As more and more pharmaceutical companies launch social networking platforms associated with their brands, some will allow users (consumers, patients, and physicians) to post comments as part of ongoing discussions about drugs and/or the conditions they treat. Recent pharma experience with social media discussions demonstrate how important it is to properly manage online communities. Perhaps the most important management tool is moderation.

By filling out the Pharma Marketing News Rate Your Social Media Marketing Readiness online questionnaire, you will discover where you may need to augment your knowledge about social media and what internal regulatory and cultural hurdles you may need to overcome to implement a social media marketing program.

This survey is designed to inform the discussion on the pros and cons of how Social, Mobile, & Gaming Technologies technologies drive patient engagement and what value they have in solving the long-standing medication adherence problem.

Before you find yourself in a social media crisis, you should have a social media implementation plan. But what are the action items for implementing your plan? This survey presents a number of actions that may be appropriate and seeks your input on how important these or other items might be in developing a plan.

This survey asks your opinion on whether or not paid inclusion should be used by pharmaceutical marketers and under what conditions.

Please take 2 minutes to answer a few short questions relating to the FDA's Revised Draft Guidance for Industry on Distributing Scientific and Medical Publications on Unapproved New Uses—Recommended Practices.

This survey asks your opinion about Pharma's use of redirect (aka 'vanity') URLS in paid search engine ads.

Did you know that a Risk Evaluation and Mitigation Strategy (REMS) can be a win-win-win situation for you, your product, and the patient? Or that the longer you wait in the product development process to start thinking about REMS, the more you will lose control of your product's future?

Now is a good time to look into our crystal balls and predict the future scenarios for the pharmaceutical industry. Let's take a slightly long-term view and predict how likely several scenarios will unfold in the next 5 to 8 years (ie, 2012 to 2019)